Real-world outcomes of NSCLC patients receiving tissue or circulating tumor DNA-guided osimertinib treatment.

Po-Lan SuSzu-Chun YangYi-Lin ChenYi-Lin WuChia-Ying LinWei-Yuan ChangYau-Lin TsengWu-Wei LaiChung-Liang HoChien-Chung LinWu-Chou Su

Published in: Cancer medicine (2019)

In this retrospective real-world analysis, it was determined that both tissue and plasma T790M mutations can be used to guide treatment with osimertinib. Similar disease control rates and survival durations were observed in comparison to those of phase 3 clinical trials.

Keyphrases

circulating tumor
small cell lung cancer
clinical trial
advanced non small cell lung cancer
cell free
epidermal growth factor receptor
circulating tumor cells
randomized controlled trial
type diabetes
metabolic syndrome
combination therapy
insulin resistance
weight loss
phase iii